Member Info for smeeagainbruce

https://gtr.ukri.org/project/B62E4643-BE4E-42AC-9AD0-A659947F2584
On and on the Affimer potential gains momentum. The need for IP mentioned.

The evaluation centre at Porton Down has passed 11 covid tests in 2022 for a market many believe to be a waste of time. A belief not shared apparently by the 11 who submitted their test. The latest test to pass being Anbio in November.
https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/outcome-of-the-evaluation-of-rapid-diagnostic-assays-for-specific-sars-cov-2-antigens-lateral-flow-devices

Yesterday about a breakthrough in the treatment for Alzheimer's using a monoclonal antibody called Lecanemab which targets the Amyloid protein.
https://www.prevention.com/health/a42110459/alzheimers-drug-lecanemab-study/
Is there an alternative to mAbs, does it have excellent binding properties. Is there any evidence out there Affimers outperform mAbs

Spot on Timster, fantastic news for Avct or do I detect a hint of sarcasm in your reply. AstraZeneca / Neogene venture is to develop TCR-Ts. AstraZeneca admits being slow on the uptake recognising the potential of this therapy hence the investment in Neogene. Avcta appointed Dr Christina Coughlin to the board of directors for her expertise in TCR-T / CAR-T
https://avacta.com/directorate-change-3/
Adding another string to our bow and therefore good news for AVCT imo, see why big Al put her on the payroll.

AstraZeneca covid treatment EVUSHED found to have its protective quality lowered by Omicron variants. Lab results later backed up by tests in humans showed the treatment was still protective but NOT AS PROTECTIVE as it was against previous variants we had in 2021. This was reported by the Blood Cancer Group months ago, AstraZeneca silent by way of an RNS. Treatment still works and saves patients' lives however why no RNS on its effectiveness against the dominant strain. Seem to remember Omicron reduced the sensitivity of an LFD and the company involved revealed the problem via an RNS. Agree LFD is not a treatment but certainly would have detected less people carrying a high viral load and this has its consequences. Evushed is sold Worldwide, privately in the UK at £1200 a pop if you can afford it.
Omicron imo will have reduced the effectiveness of the approved LFDs, why because Antibodies is the reagent and there is no proof out there it did not. PD / Yanks carried out a validation process to confirm the approved tests S&S claims were valid. .........................silence.
Evushed is a human antibody treatment derived from B cells donated by convalescent patients, and Omicron reduces its effectiveness. A common dominator emerging here.
https://bloodcancer.org.uk/news/evusheld-does-it-work-against-omicron/#:~:text=Back%20in%202021%2C%20there%20was,likely%20to%20become%20seriously%20ill.

Latest collaboration deal with Astrea BioSeparation.
Under the agreement Astrea has produced an amazing Affimer. Dr Neil gives a detailed description of the problem we face. https://www.youtube.com/watch?v=6TMW4UZNoi8
The Affimer produced not only cleanses it inhibits the ego gene from binding. Result a refined product.

Yes, I do Robin62, hold GSK shares. Unilever offered 50 BILLION POUNDS for Haleon and the offer turned down. At present Haleon worth 20 BILLION is that being naive or just stupidity.

During the covid pandemic the Centre for Virus Research in Glasgow University did the following research using Affimres.
https://www.cambridgenetwork.co.uk/news/avacta-provides-update-affimer-therapy-covid-19-infection
Conclusion ; Reagents generated to develop a covid-19 antigen test inhibited the interaction between the virus spike protein and the receptor found on human cells called ACE2 which the virus binds to as the first step in the infection.
Vaccines were the order of the day and successfully implemented however the results found by Professor David Bhella clearly demonstrates Affimers can inhibit the progression of the Coronavirus. Prove Affimers are safe to use in humans and you have an inhibitor preventing the virus binding to human cells. None of the big Pharma's showing any interest so far, to busy fiddling about with Antibodies. To be fair if you only have an inferior reagent at your disposal chance of success is limited. Affimers certainly are the future imo.

https://voice.ons.org/news-and-views/outpatient-oncology-drug-series-doxorubicin-is-the-infamous-red-devil

https://alexanderrand.com/invest/avacta-the-next-roche/

https://www.hcp.novartis.com/medical/cancer-treatment-approaches/radioligand/investigational-diagnostic-imaging-therapy/phenotypic-precision-medicine/
Treatment explained in Novartis video. Point / Lantheus use the same methodology to target the treatment. Point / Avct target the treatment using pre/CISION platform ( CanSEEK ). AVA6000 results will come first and if positive will prove Points CanSEEK works. This imo will see the FDA accelerate the trial process. Avct receive royalties + all the profits for AVA6000.
Can see a large queue forming for pre/CISION.

Avct has it covered in Chemotherapy / Radioligand Therapy. The partnership with Point allows Avct to exploit its pre/CISION platform in a therapeutic area outside of their in-house focus on Chemotherapy pro-drugs. If AVA6000 works CanSEEK works exciting times ahead for all concerned.

https://www.labpulse.com/business-insights/trends-and-finance/financial-results/article/15301732/roche-diagnostics-revenues-rise-4-for-first-nine-months-despite-sharp-drop-in-q3-covid-sales
Roche earnings for its Diagnostic sales, established in its field and about to be outperformed by Affimers.
Billions upon billions just waiting to be hoovered up by Avct Diagnostic division. Light the blue touch paper and Launch the sales into orbit.

Joining the Antibody Drug Conjugate brigade,
https://ir.adctherapeutics.com/press-releases/press-release-details/2022/ADC-Therapeutics-Announces-Abstracts-Accepted-for-Presentation-at-the-64th-ASH-Annual-Meeting/default.aspx
They are gambling on their ADC- Zynlonta, a targeted therapy that attaches to cancer cells & releases cancer killing treatment. Costly mistake, time will tell. GSK know only too well.

Mologic / GAD/ Aptamer group backed by Soros and Gates keep the business in house. Why, to control the price of their product. For me buying ABDX is a no brainer, Affimers imo will replace Antibodies as the number one reagent in the Diagnostic market worth billions of pounds. Closing the loop at today's valuation of ABDX must appear a very attractive proposition to a Company ready to dominate the Diagnostic market.

Roche with their engineered Antibody formats v Avct pre/CISION.
https://www.roche.com/stories/following-the-fibroblasts.
Pick a winner, one breaking out the stalls, the other sprinting down the home straight. Worth a £1 bet imo.

https://www.future-science.com/doi/10.2144/btn-2019-0089
From 2019 - Performance Characterisation of Affimer Reagents in PK Assay.

https://www.nature.com/articles/s41392-022-00947-7
Antibody Drug Conjugate the Biological missile for targeted cancer therapy, The V2 crude missile.
Avct, The cruise missile guided to its target with pre/CISION. Boooom.

https://www.**********.co.uk/articles/-avacta-group-says-affimer-reagents-can-prevent-covid-19-infection--1be20de/
Dr David Bhella, Centre of virus research at Glasgow Uni reported.
" Given the excellent performance of these novel reagents in the assays and the other benefits of Affimer reagents there should be considerable interest from potential partners in developing them as a therapy for Covid 19".
Nothing, another example of how far we are below the radar. Excellent performance appears not to be a positive factor in the case of Affimers outperforming Antibodies.

https://www.youtube.com/watch?v=PWrjyiR-r6o
Mutations are found in both S&N proteins, at least Avct came clean in reporting Omicron reduced Sensitivity in their LFD.
As for the approved tests, who knows. PD do and remain in silent mode since tests began 9 months ago.
The AffiDX LFD is being modified in line with information contained in the above video (2 mins in ).
Lessons Learned will play a big part in the ongoing re-development process and imo a secondary Affimer will be developed replacing the duff Antibody. Result, a cheaper test with S&S figures no other Antibody test can match.
Achieving this objective will pave the way for Affimers to replace Antibodies as the number one / the only one, reagent dominating a Diagnostic market worth £ billions.